Is hormonal therapy typically administered in conjunction with radiation therapy?
There is an abundance of clinical information demonstrating that preoperative (neoadjuvant) and postoperative (adjuvant) hormonal therapy improves survival outcomes for men with high-risk, clinically localized prostate cancer. For this reason, hormonal therapy is almost always offered in conjunction with radiotherapy for men with high-risk disease. The duration of hormonal therapy remains controversial. Because of the side efforts and unproven benefit, hormonal therapy is not offered in conjunction with radiotherapy for low-risk disease.
